Three countries have recently transferred disused radium sources to be recycled for use in cancer treatment through the IAEA’s Global Radium-226 Management Initiative. This legacy material will be transformed into actinium-225, a rare radioisotope used to treat cancers including breast and prostate cancer. To date, a total of 14 transfers from 14 countries have been completed under the initiative.
Launched in 2021, the initiative links countries holding legacy radium-226 sources with organizations equipped to produce radiopharmaceuticals using this material as feedstock. In addition to fostering these collaborative relationships, the IAEA plays an active role in transfer preparations by assisting with source inventory, characterization, conditioning and radiation monitoring.
Radium-226 was widely used in medicine and industry throughout the 20th century, but safer and more effective alternatives have since replaced it. About 100 countries have legacy stocks sitting idle in safe, secure storage, and around 80 are involved in the Global Radium-226 Management Initiative. Participating radiopharmaceutical producers convert these old sources into actinium-225 using cyclotrons – small particle accelerators that bombard the target material with charged particles, changing their fundamental composition in the process.

